{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-010348","form_type":"8-K","ticker":"CLDI","cik":"0001855485","company_name":"Calidi Biotherapeutics, Inc.","filed_at":"2025-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.190478+00:00","generated_at":"2026-05-21T10:26:20.758891+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Calidi reports Q1 net loss $5.0M; CEO transition to Eric Poma; FDA clears CLD-201 IND","bullets":["CEO transition: Eric Poma appointed CEO; 30+ yrs biopharma; raised >$250M at Molecular Templates.","FDA cleared IND for CLD-201 (allogeneic stem cell therapy) for solid tumors; CIRM non-dilutive funding.","Selected IL-15 superagonist as first payload for Redtail platform; IND filing expected H2 2026.","Q1 net loss $5.0M ($0.18/share) vs $7.2M ($2.03/share) in Q1 2024; R&D $2.4M, G&A $2.6M.","Cash $10.6M at March 31, 2025, up from $9.6M at Dec 31, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-010348","json":"https://secwatch.observer/filing/0001641172-25-010348.json","markdown":"https://secwatch.observer/filing/0001641172-25-010348.md","text":"https://secwatch.observer/filing/0001641172-25-010348.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1855485/000164117225010348/0001641172-25-010348-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1855485/000164117225010348/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T10:26:20.758891+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}